Physician profile
Roberto Panis
NPI 1346301801
$5,502.61
in general payments reported to CMS, 2019-2025
22 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $629 · 2021: $676 · 2022: $982 · 2023: $794 · 2024: $814 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,085.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $856.84 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $598.63 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $585.08 | 2022-2025 | |
| Novo Nordisk INC | $518.33 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.08 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.82 | 2019-2025 | Jardiance, Spiriva Respimat |
| Abbott Laboratories | $252.60 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $252.28 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $245.22 | 2019-2024 | Jardiance, Emgality, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $155.42 | 2019-2023 | Eliquis |
| Amgen INC. | $93.43 | 2024-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $77.79 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $75.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $28.21 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $21.69 | 2021 | |
| Ibsa Pharma INC. | $16.37 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.79 | 2020 | |
| Janssen Biotech, INC. | $14.38 | 2019 | |
| Allergan, INC. | $14.14 | 2019 | |
| Merck Sharp & Dohme LLC | $13.34 | 2019 | |
| Vivus LLC | $3.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Panis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.